SDGR vs. TARO, RCUS, LGND, SUPN, AVDL, GPCR, EWTX, HRMY, KURA, and DVAX
Should you be buying Schrödinger stock or one of its competitors? The main competitors of Schrödinger include Taro Pharmaceutical Industries (TARO), Arcus Biosciences (RCUS), Ligand Pharmaceuticals (LGND), Supernus Pharmaceuticals (SUPN), Avadel Pharmaceuticals (AVDL), Structure Therapeutics (GPCR), Edgewise Therapeutics (EWTX), Harmony Biosciences (HRMY), Kura Oncology (KURA), and Dynavax Technologies (DVAX). These companies are all part of the "pharmaceutical preparations" industry.
Taro Pharmaceutical Industries (NYSE:TARO) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
In the previous week, Schrödinger had 2 more articles in the media than Taro Pharmaceutical Industries. MarketBeat recorded 5 mentions for Schrödinger and 3 mentions for Taro Pharmaceutical Industries. Taro Pharmaceutical Industries' average media sentiment score of 0.94 beat Schrödinger's score of 0.31 indicating that Schrödinger is being referred to more favorably in the news media.
Taro Pharmaceutical Industries received 242 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 61.97% of users gave Taro Pharmaceutical Industries an outperform vote while only 55.17% of users gave Schrödinger an outperform vote.
Taro Pharmaceutical Industries presently has a consensus price target of $43.00, suggesting a potential upside of 0.73%. Schrödinger has a consensus price target of $42.80, suggesting a potential upside of 92.62%. Given Taro Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Schrödinger is more favorable than Taro Pharmaceutical Industries.
91.4% of Taro Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are owned by insiders. Comparatively, 8.6% of Schrödinger shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Taro Pharmaceutical Industries has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.
Taro Pharmaceutical Industries has a net margin of 8.56% compared to Taro Pharmaceutical Industries' net margin of -75.94%. Schrödinger's return on equity of 3.75% beat Taro Pharmaceutical Industries' return on equity.
Taro Pharmaceutical Industries has higher revenue and earnings than Schrödinger. Schrödinger is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Summary
Taro Pharmaceutical Industries beats Schrödinger on 11 of the 18 factors compared between the two stocks.
Get Schrödinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Schrödinger Competitors List
Related Companies and Tools
